Momenta

Investor Relations

NASDAQ: MNTA
Price
15.07
Change
+ 0.26
Day High
15.15
Day Low
14.75
Volume
679,800
4:00 PM ET on Mar 27, 2015
Stock price graph

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

In July 2010, the Momenta’s lead product (developed in collaboration with Sandoz) was approved as the first generic version of Lovenox® (Enoxaparin Sodium Injection).  The company’s development pipeline includes a generic version of Copaxone® (glatiramer acetate), also in collaboration with Sandoz, biosimilars in collaboration with Baxter.    necuparanib (formerly M402), a novel oncology drug candidate currently undergoing testing in early phase human clinical trials, and a portfolio of novel autoimmune drug candidates.

View Annual Report and Proxy Material

View all »   RSSRecent Releases

Mar 2, 2015
Momenta Pharmaceuticals Announces Publication Revealing Development of a Novel Process to Generate High-Quality Hyper-sialylated IVIg Drug Candidate in PNAS

Feb 18, 2015
Momenta Pharmaceuticals to Webcast Presentation at Cowen and Company's 35th Annual Health Care Conference

Feb 17, 2015
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results

Last Revised 6/12/2012